MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells

Biochemical and Biophysical Research Communications

Volumn 483, Issue 1, 2017, Pages 223-229

  Guo, Zong Pei ^a   Hu, Ying Chun ^a   Xie, Yu ^b   Jin, Feng ^c   Song, Zhi Quan ^a   Liu, Xiao Dan ^a   Ma, Teng ^a   Zhou, Ping Kun ^a,b  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

BRCA1; Double strand break; Neddylation; NSCLC; PARP1

Indexed keywords

BRCA1 PROTEIN; NEDD8 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PEVONEDISTAT; ((1S,2S,4R)-4-(4-((1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-7H-PYRROLO(2,3-D)PYRIMIDIN-7-YL)-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; ANTINEOPLASTIC AGENT; BARD1 PROTEIN, HUMAN; BRCA1 PROTEIN, HUMAN; CARRIER PROTEIN; CYCLOPENTANE DERIVATIVE; MULTIPROTEIN COMPLEX; NEDD8 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEAR PROTEIN; PARP1 PROTEIN, HUMAN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RAP80 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; DNA DAMAGE; DNA DAMAGE RESPONSE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG CANCER CELL LINE; NEDDYLATION; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MORTALITY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CELL LINE, TUMOR; CYCLOPENTANES; DNA DAMAGE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MULTIPROTEIN COMPLEXES; NUCLEAR PROTEINS; PHTHALAZINES; PIPERAZINES; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PYRIMIDINES; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

EID: 85008440543     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.12.162     Document Type: Article

References (49)

1. [1] San Filippo, J., Sung, P., Klein, H., Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 77 (2008), 229–257.
2. [2] Seluanov, A., Mao, Z., Gorbunova, V., Analysis of DNA double-strand break (DSB) repair in mammalian cells. J. Vis. Exp. JoVE, 43, 2010.
3. [3] Shrivastav, M., De Haro, L.P., Nickoloff, J.A., Regulation of DNA double-strand break repair pathway choice. Cell Res. 18 (2008), 134–147.
4. [4] Wyman, C., Kanaar, R., DNA double-strand break repair: all's well that ends well. Annu. Rev. Genet. 40 (2006), 363–383.
5. [5] Lieber, M.R., The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem. 79 (2010), 181–211.
6. [6] Prakash, R., Zhang, Y., Feng, W., Jasin, M., Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb. Perspect. Biol., 7, 2015, a016600.
7. [7] Thiriet, C., Hayes, J.J., Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. Mol. Cell 18 (2005), 617–622.
8. [8] Bartocci, C., Denchi, E.L., Put a RING on it: regulation and inhibition of RNF8 and RNF168 RING finger E3 ligases at DNA damage sites. Front. Genet., 4, 2013, 128.
9. [9] Ashley, C., Pastushok, L., McKenna, S., Ellison, M.J., Xiao, W., Roles of mouse UBC13 in DNA postreplication repair and Lys63-linked ubiquitination. Gene 285 (2002), 183–191.
10. [10] Ghosh, S., Saha, T., Central role of ubiquitination in genome maintenance: DNA replication and damage repair. ISRN Mol. Biol., 2012, 2012, 146748.
11. [11] Pastushok, L., Xiao, W., DNA postreplication repair modulated by ubiquitination and sumoylation. Adv. protein Chem. 69 (2004), 279–306.
12. [12] Starita, L.M., Parvin, J.D., The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr. Opin. Cell Biol. 15 (2003), 345–350.
13. [13] Zhou, W., Wang, X., Rosenfeld, M.G., Histone H2A ubiquitination in transcriptional regulation and DNA damage repair. Int. J. Biochem. Cell Biol. 41 (2009), 12–15.
14. [14] Bishop, D.T., BRCA1 and BRCA2 and breast cancer incidence: a review. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol./ESMO 10:Suppl 6 (1999), 113–119.
15. [15] Carter, R.F., BRCA1, BRCA2 and breast cancer: a concise clinical review. Clinical and investigative medicine. Med. Clin. Exp. 24 (2001), 147–157.
16. [16] Ewald, I.P., Ribeiro, P.L., Palmero, E.I., Cossio, S.L., Giugliani, R., Ashton-Prolla, P., Genomic rearrangements in BRCA1 and BRCA2: a literature review. Genet. Mol. Biol. 32 (2009), 437–446.
17. [17] Fuller, S., Liebens, F., Carly, B., Pastijn, A., Rozenberg, S., Breast cancer prevention in BRCA1/2 mutation carriers: a qualitative review. Breast J. 14 (2008), 603–604.
18. [18] Paterson, J.W., BRCA1: a review of structure and putative functions. Dis. Mark. 13 (1998), 261–274.
19. [19] Yang, Q., Yoshimura, G., Nakamura, M., Nakamura, Y., Suzuma, T., Umemura, T., Mori, I., Sakurai, T., Kakudo, K., BRCA1 in non-inherited breast carcinomas (Review). Oncol. Rep. 9 (2002), 1329–1333.
20. [20] Harris, J.L., Khanna, K.K., BRCA1 A-complex fine tunes repair functions of BRCA1. Aging 3 (2011), 461–463.
21. [21] Her, J., Soo Lee, N., Kim, Y., Kim, H., Factors forming the BRCA1-A complex orchestrate BRCA1 recruitment to the sites of DNA damage. Acta Biochim. Biophys. Sin. 48 (2016), 658–664.
22. [22] Matloff, E.T., Complex decision-making for BRCA1/2 carriers. Cancer J. Sci. Am. 5 (1999), 266–268.
23. [23] Savage, K.I., Harkin, D.P., BRCA1, a ‘complex’ protein involved in the maintenance of genomic stability. FEBS J. 282 (2015), 630–646.
24. [24] Wu-Baer, F., Baer, R., Effect of DNA damage on a BRCA1 complex. Nature, 414, 2001, 36.
25. [25] Bian, C., Wu, R., Cho, K., Yu, X., Loss of BRCA1-A complex function in RAP80 null tumor cells. PloS One, 7, 2012, e40406.
26. [26] Coleman, K.A., Greenberg, R.A., The BRCA1-RAP80 complex regulates DNA repair mechanism utilization by restricting end resection. J. Biol. Chem. 286 (2011), 13669–13680.
27. [27] Wu, J., Liu, C., Chen, J., Yu, X., RAP80 protein is important for genomic stability and is required for stabilizing BRCA1-A complex at DNA damage sites in vivo. J. Biol. Chem. 287 (2012), 22919–22926.
28. [28] Ma, T., Chen, Y., Zhang, F., Yang, C.Y., Wang, S., Yu, X., RNF111-dependent neddylation activates DNA damage-induced ubiquitination. Mol. Cell 49 (2013), 897–907.
29. [29] Schmidt, M.H., Dikic, I., Ubiquitin and NEDD8: brothers in arms. Sci. STKE Signal Transduct. Knowl. Environ., 2006, 2006, pe50.
30. [30] Whitby, F.G., Xia, G., Pickart, C.M., Hill, C.P., Crystal structure of the human ubiquitin-like protein NEDD8 and interactions with ubiquitin pathway enzymes. J. Biol. Chem. 273 (1998), 34983–34991.
31. [31] Kamitani, T., Kito, K., Nguyen, H.P., Yeh, E.T., Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J. Biol. Chem. 272 (1997), 28557–28562.
32. [32] Gayther, S.A., Warren, W., Mazoyer, S., Russell, P.A., Harrington, P.A., Chiano, M., Seal, S., Hamoudi, R., van Rensburg, E.J., Dunning, A.M., Love, R., Evans, G., Easton, D., Clayton, D., Stratton, M.R., Ponder, B.A., Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat. Genet. 11 (1995), 428–433.
33. [33] Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R.K., Wardley, A., Mitchell, G., Earl, H., Wickens, M., Carmichael, J., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376 (2010), 235–244.
34. [34] Audeh, M.W., Carmichael, J., Penson, R.T., Friedlander, M., Powell, B., Bell-McGuinn, K.M., Scott, C., Weitzel, J.N., Oaknin, A., Loman, N., Lu, K., Schmutzler, R.K., Matulonis, U., Wickens, M., Tutt, A., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376 (2010), 245–251.
35. [35] Garcia, K., Blank, J.L., Bouck, D.C., Liu, X.J., Sappal, D.S., Hather, G., Cosmopoulos, K., Thomas, M.P., Kuranda, M., Pickard, M.D., Liu, R., Bandi, S., Smith, P.G., Lightcap, E.S., Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways. Mol. Cancer Ther. 13 (2014), 1625–1635.
36. [36] Nawrocki, S.T., Kelly, K.R., Smith, P.G., Espitia, C.M., Possemato, A., Beausoleil, S.A., Milhollen, M., Blakemore, S., Thomas, M., Berger, A., Carew, J.S., Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 19 (2013), 3577–3590.
37. [37] Ho, I.L., Kuo, K.L., Liu, S.H., Chang, H.C., Hsieh, J.T., Wu, J.T., Chiang, C.K., Lin, W.C., Tsai, Y.C., Chou, C.T., Hsu, C.H., Pu, Y.S., Shi, C.S., Huang, K.H., MLN4924 synergistically enhances cisplatin-induced cytotoxicity via JNK and Bcl-xL pathways in human urothelial carcinoma. Sci. Rep., 5, 2015, 16948.
38. [38] Lin, W.C., Kuo, K.L., Shi, C.S., Wu, J.T., Hsieh, J.T., Chang, H.C., Liao, S.M., Chou, C.T., Chiang, C.K., Chiu, W.S., Chiu, T.Y., Pu, Y.S., Ho, I.L., Wang, Z.H., Chang, S.C., Liu, S.H., Jeng, Y.M., Huang, K.H., MLN4924, a Novel NEDD8-activating enzyme inhibitor, exhibits antitumor activity and enhances cisplatin-induced cytotoxicity in human cervical carcinoma: in vitro and in vivo study. Am. J. Cancer Res. 5 (2015), 3350–3362.
39. [39] Kee, Y., Huang, M., Chang, S., Moreau, L.A., Park, E., Smith, P.G., D'Andrea, A.D., Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents. Mol. Cancer Res. MCR 10 (2012), 369–377.
40. [40] Jazaeri, A.A., Shibata, E., Park, J., Bryant, J.L., Conaway, M.R., Modesitt, S.C., Smith, P.G., Milhollen, M.A., Berger, A.J., Dutta, A., Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol. Cancer Ther. 12 (2013), 1958–1967.
41. [41] Han, J., Zhang, H., Wang, Z., Zhou, H., Zhang, Z., A Cul4 E3 ubiquitin ligase regulates histone hand-off during nucleosome assembly. Cell 155 (2013), 817–829.
42. [42] Hannah, J., Zhou, P., Regulation of DNA damage response pathways by the cullin-RING ubiquitin ligases. DNA Repair 8 (2009), 536–543.
43. [43] Lok, B.H., Gardner, E.E., Schneeberger, V.E., Ni, A., Desmeules, P., Rekhtman, N., de Stanchina, E., Teicher, B.A., Riaz, N., Powell, S.N., Poirier, J.T., Rudin, C.M., PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2016 CCR-16-1040.
44. [44] Juvekar, A., Burga, L.N., Hu, H., Lunsford, E.P., Ibrahim, Y.H., Balmana, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C.A., Nardella, C., Pandolfi, P.P., Baselga, J., Scully, R., Asara, J.M., Cantley, L.C., Wulf, G.M., Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2 (2012), 1048–1063.
45. [45] Evers, B., Drost, R., Schut, E., de Bruin, M., van der Burg, E., Derksen, P.W., Holstege, H., Liu, X., van Drunen, E., Beverloo, H.B., Smith, G.C., Martin, N.M., Lau, A., O'Connor, M.J., Jonkers, J., Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 14 (2008), 3916–3925.
46. [46] Srivastava, M., Raghavan, S.C., DNA double-strand break repair inhibitors as cancer therapeutics. Chem. Biol. 22 (2015), 17–29.
47. [47] Brown, J.S., Lukashchuk, N., Sczaniecka-Clift, M., Britton, S., le Sage, C., Calsou, P., Beli, P., Galanty, Y., Jackson, S.P., Neddylation promotes ubiquitylation and release of Ku from DNA-damage sites. Cell Rep. 11:5 (5 May 2015), 704–714.
48. [48] Gyorffy, B., Surowiak, P., Budczies, J., Lanczky, A., Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One, 8, 2013.
49. [49] Li, M., Yu X.Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell. 23 (2013), 693–704.